Adverse effects of azacitidine: onset, duration, and treatment (Q34193934)

31 July 2017

1 reference

title

Adverse effects of azacitidine: onset, duration, and treatment (English)

1 reference

31 July 2017

Antonio Martínez-Francés

series ordinal

1

1 reference

PubMed ID

21688206

31 July 2017

language of work or name

English

0 references

publication date

8 June 2011

1 reference

31 July 2017

1 reference

31 July 2017

28 Suppl 4

1 reference

31 July 2017

1-5

1 reference

https://scigraph.springernature.com/pub.10.1007/s12325-011-0017-1

31 July 2017

0 references

cites work

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0017-1

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0017-1

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0017-1

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0017-1

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0017-1

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0017-1

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0017-1

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0017-1

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0017-1

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0017-1

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0017-1

Extended adjuvant endocrine therapy in breast cancer: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0017-1

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0017-1

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0017-1

Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0017-1

Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0017-1

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0017-1

Adjuvant aromatase inhibitor therapy: outcomes and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0017-1

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0017-1

Practical guidance for the management of aromatase inhibitor-associated bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0017-1

Tracking women's awareness of heart disease: an American Heart Association national study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0017-1

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0017-1

10.1007/S12325-011-0017-1

21 January 2018

Identifiers

DOI

1 reference

PubMed ID

21688206

Dimensions Publication ID

31 July 2017

0 references

1 reference

PubMed ID

21688206